2. Class members
Opioid (or opioid combination) | Oral formulations | Other formulations |
|---|---|---|
Alfentanil | Injection | |
Buprenorphine | Sublingual tablets | Injection |
Buprenorphine + naloxone | Sublingual tablets | |
Codeine | Tablets | Injection |
Codeine + aspirin (co-codaprin) | Dispersible tablets | |
Codeine + paracetamol (co-codamol) | Tablets | |
Diamorphine | Tablets | Injection |
Dihydrocodeine | Tablets | Injection |
Dihydrocodeine + paracetamol (including co-dydramol) | Tablets | |
Dipipanone + cyclizine | Tablets | |
Fentanyl | Buccal tablets | Injection |
Hydromorphone | Capsules | |
Meptazinol | Tablets | Injection |
Methadone | Tablets | Injection |
Morphine | Tablets | Injection |
Morphine + cyclizine | Injection | |
Oxycodone | Modified-release tablets | Injection |
Oxycodone + naloxone | Tablets | |
Papaveretum | Injection | |
Papaveretum + hyoscine hydrobromide | Injection | |
Pentazocine | Tablets | Injection |
Pethidine | Tablets | Injection |
Pethidine + promethazine | Injection | |
Remifentanil | Injection | |
Tapentadol | Tablets | |
Tramadol | Capsules | Injection |
Tramadol + paracetamol | Tablets |
Did you know …
In England, more than one in every ten primary care prescriptions for opioids is for transdermal patches?
Buprenorphine and fentanyl transdermal patches are not suitable for acute pain—they should be used for chronic pain only.
Activity 1
Some formulations of opioid medicines include an opioid antagonist1. Which antagonist is used? Give two reasons for including the antagonist in the formulation.
- A substance that binds to a receptor but produces no effect and inhibits an agonist from binding to the receptor↩